CAAS Capital Management’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

CAAS Capital Management’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-33,333	Closed	-$9.93K	–	1022
2022 Q4	$9.93K	Hold	33,333	–	–	﹤0.01%	694
2022 Q3	$3K	Hold	33,333	–	–	﹤0.01%	766
2022 Q2	$5K	Buy	+33,333	New	+$5.64K	﹤0.01%	817
2022 Q1	–	Sell	-33,333	Closed	-$20K	–	1041
2021 Q4	$20K	Hold	33,333	–	–	﹤0.01%	802
2021 Q3	$21K	Buy	+33,333	New	+$25.9K	﹤0.01%	875

CAAS Capital Management's EBACW Position: Q1 2023 in Review

CAAS Capital Management sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 33,333 shares — an estimated $9.93K sold.

CAAS Capital Management first reported a position in EBACW in Q3 2021 and held it in 5 quarters. The position peaked at $21K in Q3 2021. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

CAAS Capital Management reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
CAAS Capital Management sold 33,333 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $9.93K.
CAAS Capital Management first reported a position in European Biotech Acquisition Corp. Warrant in Q3 2021 and held it in 5 quarters.
CAAS Capital Management's European Biotech Acquisition Corp. Warrant position peaked at $21K in Q3 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.